Kancera AB (publ) (KAN.ST)
SEK 1.22
(9.09%)
SEK 1.22
(9.09%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.03 Million SEK | 37.45% |
| 2022 | 753 Thousand SEK | -55.81% |
| 2021 | 1.7 Million SEK | 1793.33% |
| 2020 | 90 Thousand SEK | -97.2% |
| 2019 | 3.21 Million SEK | 798.32% |
| 2018 | 358 Thousand SEK | 216.81% |
| 2017 | 113 Thousand SEK | -63.31% |
| 2016 | 308 Thousand SEK | 9.22% |
| 2015 | 282 Thousand SEK | -40.0% |
| 2014 | 470 Thousand SEK | -74.08% |
| 2013 | 1.81 Million SEK | -52.77% |
| 2012 | 3.83 Million SEK | -45.69% |
| 2011 | 7.06 Million SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 Q3 | - SEK | -100.0% |
| 2023 Q4 | 443 Thousand SEK | 0.0% |
| 2023 FY | 1.03 Million SEK | 37.45% |
| 2023 Q2 | 456 Thousand SEK | 235.29% |
| 2023 Q1 | 136 Thousand SEK | 403.7% |
| 2022 Q4 | 27 Thousand SEK | -87.73% |
| 2022 Q3 | 220 Thousand SEK | -3.08% |
| 2022 Q1 | 279 Thousand SEK | -75.46% |
| 2022 Q2 | 227 Thousand SEK | -18.64% |
| 2022 FY | 753 Thousand SEK | -55.81% |
| 2021 Q4 | 1.13 Million SEK | 173.32% |
| 2021 FY | 1.7 Million SEK | 1793.33% |
| 2021 Q1 | 565 Thousand SEK | 112.1% |
| 2021 Q2 | - SEK | -100.0% |
| 2021 Q3 | 416 Thousand SEK | 0.0% |
| 2020 Q2 | 3.57 Million SEK | 8609.76% |
| 2020 FY | 90 Thousand SEK | -97.2% |
| 2020 Q3 | 49 Thousand SEK | -98.63% |
| 2020 Q4 | -4.67 Million SEK | -9632.65% |
| 2020 Q1 | 41 Thousand SEK | 132.28% |
| 2019 Q1 | 3.11 Million SEK | 884.49% |
| 2019 FY | 3.21 Million SEK | 798.32% |
| 2019 Q4 | -127 Thousand SEK | -152.05% |
| 2019 Q3 | 244 Thousand SEK | -62.35% |
| 2019 Q2 | 648 Thousand SEK | -79.17% |
| 2018 Q4 | 316 Thousand SEK | 401.59% |
| 2018 FY | 358 Thousand SEK | 216.81% |
| 2018 Q3 | 63 Thousand SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2017 FY | 113 Thousand SEK | -63.31% |
| 2017 Q2 | 86 Thousand SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q4 | 27 Thousand SEK | 0.0% |
| 2016 Q3 | 42 Thousand SEK | 133.33% |
| 2016 Q1 | 114 Thousand SEK | 660.0% |
| 2016 FY | 308 Thousand SEK | 9.22% |
| 2016 Q4 | 134 Thousand SEK | 219.05% |
| 2016 Q2 | 18 Thousand SEK | -84.21% |
| 2015 Q4 | 15 Thousand SEK | -91.8% |
| 2015 FY | 282 Thousand SEK | -40.0% |
| 2015 Q1 | 10 Thousand SEK | -80.0% |
| 2015 Q3 | 183 Thousand SEK | 147.3% |
| 2015 Q2 | 74 Thousand SEK | 640.0% |
| 2014 Q2 | 153 Thousand SEK | -27.83% |
| 2014 Q4 | 50 Thousand SEK | -9.09% |
| 2014 FY | 470 Thousand SEK | -74.08% |
| 2014 Q3 | 55 Thousand SEK | -64.05% |
| 2014 Q1 | 212 Thousand SEK | -84.34% |
| 2013 Q4 | 1.35 Million SEK | 461.83% |
| 2013 Q3 | 241 Thousand SEK | 10.55% |
| 2013 Q2 | 218 Thousand SEK | 0.0% |
| 2013 FY | 1.81 Million SEK | -52.77% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q3 | 953 Thousand SEK | 74.86% |
| 2012 Q1 | 657 Thousand SEK | -79.62% |
| 2012 Q4 | 1.68 Million SEK | 76.71% |
| 2012 FY | 3.83 Million SEK | -45.69% |
| 2012 Q2 | 545 Thousand SEK | -17.05% |
| 2011 Q1 | 592 Thousand SEK | 0.0% |
| 2011 Q2 | 1.66 Million SEK | 180.57% |
| 2011 Q3 | 1.59 Million SEK | -4.15% |
| 2011 Q4 | 3.22 Million SEK | 102.51% |
| 2011 FY | 7.06 Million SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 98.219% |
| Ziccum AB (publ) | 3.74 Million SEK | 72.378% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.832% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 97.95% |
| Mendus AB (publ) | 28.48 Million SEK | 96.367% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.346% |
| Intervacc AB (publ) | 8.01 Million SEK | 87.087% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 76.337% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.393% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 97.642% |
| Aptahem AB (publ) | 2.63 Million SEK | 60.656% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1244.156% |
| Fluicell AB (publ) | 3.33 Million SEK | 68.993% |
| Saniona AB (publ) | 16.84 Million SEK | 93.854% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 93.692% |
| Biovica International AB (publ) | 7.29 Million SEK | 85.802% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 13.965% |
| AcouSort AB (publ) | 10.55 Million SEK | 90.191% |
| Xintela AB (publ) | 78 Thousand SEK | -1226.923% |
| Abliva AB (publ) | 137 Thousand SEK | -655.474% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 98.203% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 48.61% |
| OncoZenge AB (publ) | 3000.00 SEK | -34400.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -567.742% |
| CombiGene AB (publ) | 5.54 Million SEK | 81.332% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.914% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.94% |
| Corline Biomedical AB | 25.03 Million SEK | 95.865% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 81.772% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -43.551% |
| I-Tech AB | 120.86 Million SEK | 99.144% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.228% |
| Cyxone AB (publ) | 5.14 Million SEK | 79.895% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 85.319% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 90.295% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 90.784% |
| Nanologica AB (publ) | 1.44 Million SEK | 28.274% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -1852.83% |
| BioInvent International AB (publ) | 71.46 Million SEK | 98.552% |
| Alzinova AB (publ) | 270 Thousand SEK | -283.333% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 97.061% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 29.256% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 63.324% |
| Simris Alg AB (publ) | 4.35 Million SEK | 76.229% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -696.154% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.566% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -4400.0% |